{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:41Z","timestamp":1791915881063,"version":"4.3.4"},"reference-count":37,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"abstract":"<jats:p>&lt;p&gt;Introduction: The safety of biologics, other than TNF-\u03b1 inhibitors, during pregnancy has not been sufficiently established. To assess the risk of pregnancy-related adverse outcomes of biologics used for psoriasis, compared to TNF-\u03b1 inhibitors, we utilized the WHO global pharmacovigilance database (1968\u20132024). Methods: We utilized the World Health Organization\u2019s global pharmacovigilance database from 1968 to 2024. From over 140 million reports from more than 170 countries, we extracted 6,518 reports of pregnancy-related adverse outcomes associated with the biologics of interest. These biologics included TNF-\u03b1 inhibitors (e.g., etanercept, infliximab, adalimumab, certolizumab pegol), IL-12\/IL-23 inhibitor (e.g., ustekinumab), IL-17 inhibitors (e.g., secukinumab, brodalumab, ixekizumab, bimekizumab), and IL-23 inhibitors (e.g., guselkumab, tildrakizumab, risankizumab). Each biologic was compared to TNF-\u03b1 inhibitors and certolizumab pegol in two separate disproportionality analyses. The reporting odds ratio (ROR) was calculated for maternal, fetal, and neonatal outcomes, categorized into seven major groups. Multivariable and sensitivity analyses were conducted to validate the primary results. Results: The disproportionality analysis showed that, compared to TNF-\u03b1 inhibitors, most biologics had a lower frequency of pregnancy-related adverse outcomes, with the exception of brodalumab. Specifically, ROR and 95% confidence intervals (CIs) were as follows: ustekinumab (ROR, 0.27; 95% CI: 0.21\u20130.35), secukinumab (0.17; 0.13\u20130.22), brodalumab (0.20; 0.02\u20132.21), ixekizumab (0.05; 0.03\u20130.08), bimekizumab (0.10; 0.01\u20130.71), guselkumab (0.09; 0.05\u20130.15), tildrakizumab (0.02; 0.00\u20130.14), and risankizumab (0.38; 0.25\u20130.58). However, risankizumab was reported with a higher frequency of abortion and stillbirth (1.87; 1.32\u20132.63). These findings were consistent when compared to certolizumab pegol, as well as in multivariable and sensitivity analyses. Furthermore, when comparing other TNF-\u03b1 inhibitors to certolizumab pegol, infliximab showed a lower frequency of pregnancy-related adverse outcomes (ROR, 0.71; 95% CI: 0.55\u20130.92), etanercept showed a comparable frequency (1.00; 0.77\u20131.31), and adalimumab showed a higher frequency (1.42; 1.11\u20131.81). Conclusions: Biologics used for psoriasis, with the exception of brodalumab, exhibit a lower frequency of pregnancy-related adverse outcomes compared to TNF-\u03b1 inhibitors and certolizumab pegol, suggesting their potential to be safe options during pregnancy. However, further studies are necessary to evaluate the safety of these biologics during pregnancy, accounting for confounding factors. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000542217","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:02:05Z","timestamp":1733227325000},"page":"579-593","source":"Crossref","is-referenced-by-count":23,"title":["Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study"],"prefix":"10.1159","volume":"186","author":[{"given":"Yi Deun","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyesu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanseul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonwoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19169"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.004"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.5.601"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14547"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2923"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15423"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19238"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.5595"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15671"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.072"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29682"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14250"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.39934"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5625"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/all.16304"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29792"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15802"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01376-y"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa064"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102676"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.005"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16448"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad347"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2012.1116"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16192"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17224"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16901"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18897"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.196"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077664"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2019-11-6"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/iaa\/article-pdf\/doi\/10.1159\/000542217\/4308587\/000542217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000542217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:04:09Z","timestamp":1758297849000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000542217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,5,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000542217","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.27313983","asserted-by":"subject"}]},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}